scholarly journals Primary Malignant Melanoma of the Cervix: A Case Report and a Review of the Literature

2020 ◽  
Vol 2020 ◽  
pp. 1-9
Author(s):  
Michail Diakosavvas ◽  
Zacharias N. Fasoulakis ◽  
Maria Kouroupi ◽  
Marianna Theodora ◽  
Lola Inagamova ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Radical Hysterectomy ◽  
Treatment Guidelines ◽  
Treatment Options ◽  
Staging System ◽  
Surgical Excision ◽  
Figo Stage ◽  
Pelvic Lymphadenectomy ◽  
Primary Malignant Melanoma ◽  
Treatment Modalities

Background. Gynecologic melanomas are extremely rare malignancies, and primary malignant melanoma of the cervix (PMMC) is the rarest among them all, with less than 100 cases reported so far. Although some conditions have been correlated with the pathogenesis of this entity, no specific risk factor has been yet identified, with vaginal bleeding being the most common symptoms. The diagnosis is based on physical examination with speculum assessment and cytologic and histopathologic findings accompanied with immunohistochemical staining of lesion’s biopsies. Case Presentation. We report a case of PMMC in a 34-year-old para-2 patient, among the youngest cases of PMMC reported, that presented to our clinic for routine examination. Gynecologic examination demonstrated a dark, heavily fully pigmented cervical growth completely covering the entire external cervical os. Biopsy obtained and showed malignant melanoma. She underwent radical hysterectomy with bilateral salpingo-oophorectomy and pelvic lymphadenectomy. The pathological diagnosis was FIGO stage IB1 PMMC. Despite 2 courses of anti-PD-1 antibody (Nivolumab) treatment, the patient passed away 13 months after diagnosis (12 months after surgery). Conclusions. Early diagnosis and subsequently early treatment are of high importance regarding patients’ prognosis and survival. No standardized protocols or treatment guidelines specific for this rare cancer have been issued; thus, clinicians are called to assess each case individually. Current treatment options are based on surgical excision mostly with radical hysterectomy, but in advanced or recurrent state of the disease, other treatment modalities, such as chemotherapy, radiotherapy, and immunotherapy, can be employed. Prognosis for these patients is very poor, and survival rate remains extremely low, with the median OS reported being less than 2 years. Reporting and publishing of such cases are both of paramount importance for the better understanding of this uncommon cervical malignancy, and further biological and clinical investigations are required for more suitable and effective therapies to be determined. A new staging system, specific to PMMC, could be of great use for the better correlation of the disease’s stage and prognosis of these patients.

scholarly journals Primary malignant melanoma of the uterine cervix treated with radical surgery and adjuvant chemo-radiation using temozolomide and cisplatin: a case report

2019 ◽  
Vol 8 (8) ◽  
pp. 3387
Author(s):  
Goter Doke ◽  
Shyam Tsering ◽  
Hage Nobin ◽  
Dacto Gara
Keyword(s):  
Case Report ◽  
Malignant Melanoma ◽  
Uterine Cervix ◽  
Radical Hysterectomy ◽  
Vaginal Bleeding ◽  
Radical Surgery ◽  
Pelvic Lymphadenectomy ◽  
Primary Malignant Melanoma ◽  
Rare Neoplasm

Primary malignant melanoma of the uterine cervix is a rare neoplasm and the overall prognosis of patients with this disease is very poor. Herein, authors report a case of 45-year-old woman who presented with vaginal bleeding for one months and examination showed an exophytic, 6 cm polypoid blackish-pigmented tumor on the cervix involving vaginal fornix. She underwent abdominal radical hysterectomy with bilateral salpingo-oophorectomy and pelvic lymphadenectomy and further received adjuvant concurrent chemo-radiation with cisplatin (CDDP) and temozolamide but died 7 months after surgery.

Zosteriform Nevus Comedonicus

2020 ◽  
Vol 11 (SPL4) ◽  
pp. 2609-2612
Author(s):  
Babbita S ◽  
Thillaikkarasi A ◽  
Sathyanarayanana R ◽  
Narasimhalu CRV ◽  
Sulochana Sonti
Keyword(s):  
Topical Therapy ◽  
Treatment Options ◽  
Neck Region ◽  
Surgical Excision ◽  
Hair Follicles ◽  
Treatment Modalities ◽  
Developmental Defect ◽  
Linear Distribution ◽  
Head And Neck Region ◽  
Typical Morphology

Nevus comedonicus is an uncommon cutaneous developmental defect of follicular apparatus characterized by unilateral and linear distribution of bundles of dilated hair follicles filled with keratin plugs. It is usually seen on the head and neck region, trunk and upper arm. This condition may be present at birth or can occur later in life. The term nevus comedonicus is a misnomer as there are no true comedones and is better termed as follicular keratotic nevus. It is also known as nevus zoniforme or nevus acneiformis unilateralis. There are two types of nevus comedonicus, namely inflammatory and non-inflammatory (non-pyogenic). When nevus comedonicus is manifested with other extracutaneous symptoms, it is termed as nevus comedonicus syndrome. Diagnosis is mainly clinical, based on history and typical morphology. As the disease runs a benign course, no aggressive treatment is required. Patients seek treatment, especially for cosmetic purposes and inflammatory type of lesions. Various treatment modalities like topical therapy, surgical excision, lasers are available and treatment options are individualized based on the size and extent of the lesion. We herein present a case of unilateral nevus comedonicus with no systemic associations in a 30-year-old female on her lower limb which is not a common site of occurrence.

scholarly journals A Case of Malignant Melanoma of the Uterine Cervix with Disseminated Metastases throughout the Vaginal Wall

2017 ◽  
Vol 2017 ◽  
pp. 1-4 ◽  
Author(s):  
Tomoko Noguchi ◽  
Nami Ota ◽  
Yasushi Mabuchi ◽  
Shigetaka Yagi ◽  
Sawako Minami ◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Uterine Cervix ◽  
Pap Smear ◽  
Lung Metastases ◽  
Female Genital Tract ◽  
Figo Stage ◽  
Vaginal Wall ◽  
Pelvic Lymphadenectomy ◽  
Pigmented Lesions ◽  
Node Metastases

Malignant melanoma (MM) in the female genital tract accounts for less than 2% of all melanomas, and the vast majority associated occur in the vulva and vagina. Primary MM of the uterine cervix is extremely rare and its prognosis is very poor. We report a case of primary MM of the cervix with dissemination throughout the vaginal wall. A 66-year-old woman presented with postmenopausal bleeding. Gynecologic examination demonstrated a 2 cm polypoid blackish-pigmented tumor on the cervix with multiple small blackish-pigmented lesions throughout the vaginal wall. Cervical Pap smear cytology showed malignant melanoma. MRI and PET/CT did not detect any distant or lymph node metastases. She underwent radical hysterectomy, pelvic lymphadenectomy, and total vaginectomy. The pathological diagnosis was FIGO stage IIIA primary cervical MM. She received adjuvant chemotherapy with 6 courses of dacarbazine, but 6 months later, multiple lung metastases were detected. Despite 4 courses of anti-PD-1 antibody (nivolumab) treatment, she died of the disease 13 months after surgery.

scholarly journals Primary retromolar malignant melanoma in a Latin American patient

2020 ◽  
Vol 48 (4) ◽  
pp. 030006052091924
Author(s):  
Carlos-Martín Ardila ◽  
Joan-Michael Arce-Jaramillo ◽  
Efraín Álvarez-Martínez
Keyword(s):  
Latin America ◽  
Malignant Melanoma ◽  
Latin American ◽  
Surgical Excision ◽  
Primary Malignant Melanoma ◽  
Ki 67 ◽  
Metastatic Lesions ◽  
Immunohistochemistry Staining ◽  
American Patient ◽  
Hmb 45

Primary malignant melanoma of the oral mucosa is rare and has scarcely been reported in patients from Latin America. The most frequently affected sites include the palate and gingiva of the maxilla. In this report, we describe primary malignant melanoma in a Latin American patient. A 3 × 3.5-cm black tumor was observed on the upper left retromolar area. The lesion exhibited a sessile base, irregular edges, soft consistency, and pain on palpation. Immunohistochemistry staining results were positive for S100 and HMB-45; the Ki-67 index was 20%. Contrast tomography of the skull, face, abdomen, and thorax, as well as ultrasound of the liver, did not reveal metastatic lesions. The patient underwent wide surgical excision of the lesion, followed by radiotherapy; he was subsequently rehabilitated with a somato prosthesis.

scholarly journals Treatment Reality of Patients with Immune Thrombocytopenia (ITP) in Routine Care

Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 5009-5009
Author(s):  
Rudolf Weide ◽  
Stefan Feiten ◽  
Vera Friesenhahn ◽  
Jochen Heymanns ◽  
Kristina Kleboth ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Biopsy ◽  
Treatment Guidelines ◽  
Conflicts Of Interest ◽  
Treatment Options ◽  
Immunosuppressive Agents ◽  
Routine Care ◽  
Treatment Modalities ◽  
Bleeding Complications ◽  
Line Therapy

Abstract Introduction: New treatment options like thrombopoietin receptor agonists (TRAs) and rituximab have been introduced into the clinic which have found their way into national and international treatment guidelines. The aim of this study was to answer the following questions concerning diagnosis and treatment of patients with ITP in routine care: How are patients diagnosed and treated?Which sequences of therapy are applied?How many patients die due to bleeding complications? Methods: All patients with ITP diagnosed between 06/1995-06/2014 in a community-based oncology group practice in Germany were analyzed retrospectively. Results: 402 patients with a median age of 55 (7-90) were evaluated. 57% were female and 43% male. 357 (89%) were classified as primary ITP and 311 (77%) as having chronic ITP. In 234 patients (58%) a bone marrow biopsy was part of the diagnostic work up. Only 191 patients (48%) needed therapy. First line therapy (n=191) were steroids in 81%, intravenous immunoglobulins (ivIgG) in 12% and ivIgG plus steroids in 6%. Second line therapy (n=102) were ivIgG in 49%, steroids in 23%, ivIgG plus steroids in 17%, other immunosuppressive agents in 11% and splenectomy in 5%. Third line therapy (n=63) was splenectomy in 22%, other immunosuppressive agents in 27%, steroids in 19%, ivIgG in 16%, 11% combination therapy, rituximab in 10% and TRAs in 5%. Fourth line therapy (n=38) consisted of steroids in 26%, splenectomy in 26%, immunosuppressive agents in 34%, ivIgG in 13%, rituximab in 11% and TRAs in 3%. Patients received a median of 2 lines (1-10) of therapy. Treatment modalities most frequently used were steroids in 93%, immunoglobulins in 56%, splenectomy in 21% and other immunosuppressive agents in 21% of patients. Rituximab and TRAs were used in 10% and 5% only. 75% of patients received a durable remission (complete or partial) after their last therapy. 10% showed no response, in 15% remission couldn't be evaluated due to external treatments. 146 patients (76%) are off treatment. 1 patient (0.2%) died due to bleeding complications. Conclusions: Bone marrow biopsy is used as a diagnostic procedure in 58% of patients. Treatment modalities most frequently used are steroids, immunoglobulins, splenectomy and other immunosuppressive agents. Rituximab and TRAs are used infrequently. A high percentage of ITP-patients achieve durable remissions and ITP-related mortality is low. Disclosures No relevant conflicts of interest to declare.

Management of congenital subglottic hemangioma: Trends and success over the past 17 years

2005 ◽  
Vol 132 (2) ◽  
pp. 226-231 ◽  
Author(s):  
Mohamed A. Bitar ◽  
Roger V. Moukarbel ◽  
George H. Zalzal
Keyword(s):  
Carbon Dioxide ◽  
Side Effects ◽  
Success Rate ◽  
Study Design ◽  
Complication Rate ◽  
Carbon Dioxide Laser ◽  
Treatment Options ◽  
Surgical Excision ◽  
Treatment Modalities ◽  
The Past

OBJECTIVE: To evaluate the success and complications of various treatment options of congenital subglottic hemangioma. STUDY DESIGN AND SETTINGS: Reported cases were grouped by treatment modalities and corresponding outcome evaluated. RESULTS: From 1986 through 2002, 372 patients were reported in 28 series. Carbon dioxide laser had 88.9% success rate yet 5.5 % significant subglottic stenosis. It shortened the tracheotomy duration by 13.7 months. Corticosteroids were not that beneficial (useful in only 24.5%) with 12.9% side effects. Intralesional corticosteroids were successful in 86.4% with 5.6% complication rate. Surgical excision (as young as 2.5 months), was useful in 98% with 10% complication rate, using cartilage grafts in 34%. Other modalities were less popular. CONCLUSION: Treatment should be individualized. Guidelines are suggested. Priority is given to secure the airways. The CO2 laser is useful when used cautiously. Steroids may be beneficial. Excision is for stubborn cases.

Tolerability of toceranib phosphate (Palladia) when used in conjunction with other therapies in 35 cats with feline oral squamous cell carcinoma: 2009–2013

2016 ◽  
Vol 19 (6) ◽  
pp. 568-575 ◽  
Author(s):  
Gina A Olmsted ◽  
John Farrelly ◽  
Gerald S Post ◽  
Jaclyn Smith
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Squamous Cell ◽  
Treatment Options ◽  
Surgical Excision ◽  
Current Treatment ◽  
Treatment Modalities ◽  
Low Grade ◽  
Treatment Delays ◽  
Gi Toxicity

Objectives Squamous cell carcinoma (SCC) is the most common oral tumor in cats and typically carries a poor prognosis with current treatment options. The objective of this study was to evaluate the toxicity of toceranib phosphate (Palladia; Pfizer) in cats with oral SCC in combination with other treatment modalities. Methods In this study, 35 cats were retrospectively evaluated to determine toxicity when treated with toceranib in combination with other treatment modalities. Cats received toceranib at a median dose of 2.75 mg/kg (range 1.9–4.17 mg/kg) 3 days a week. Cats also underwent additional therapies, including surgical excision, radiation therapy, chemotherapy and/or use of non-steroidal anti-inflammatory drugs. Results Toxicity was seen in six cats, with five cases of grade 1 or 2 gastrointestinal (GI) toxicity and one grade 4 metabolic toxicity. Toceranib was discontinued in one cat and two cats received dose reductions. None of the cats required treatment delays or hospitalization due to toxicity. Median toceranib treatment duration was 77 days (range 7–741 days). Conclusions and relevance This study revealed that toceranib was well tolerated by the majority of cats, with five cases of low-grade GI toxicity and one case of metabolic toxicity. Given the favorable toxicity profile, future studies further evaluating the safety and efficacy of toceranib for cats with oral SCC should be considered.

scholarly journals Effect of the Number of Removed Lymph Nodes on Survival in Patients with FIGO Stage IB-IIA Cervical Squamous Cell Carcinoma following Open Radical Hysterectomy with Pelvic Lymphadenectomy: A Retrospective Cohort Study

2021 ◽  
Vol 2021 ◽  
pp. 1-11
Author(s):  
Qinhao Guo ◽  
Yong Wu ◽  
Hao Wen ◽  
Xingzhu Ju ◽  
Xiaohua Wu
Keyword(s):  
Squamous Cell Carcinoma ◽  
Regression Analysis ◽  
Prognostic Factor ◽  
Radical Hysterectomy ◽  
Cox Regression ◽  
Figo Stage ◽  
Cervical Squamous Cell Carcinoma ◽  
Pelvic Lymphadenectomy ◽  
Cox Regression Analysis ◽  
Stage Ib

Objective. To determine whether the number of removed lymph nodes (RLN) is associated with survival in patients with International Federation of Gynecology and Obstetrics (FIGO) stage IB-IIA cervical squamous cell carcinoma (CSCC). Methods. We reviewed the medical records of FIGO stage IB-IIA CSCC patients who underwent standardized radical hysterectomy with pelvic lymphadenectomy (RHPL) in our center between 2006 and 2014. The X-tile software was performed to calculate the optimal grouping of cutoff points for RLN. The impact of RLN on progression-free survival (PFS) and overall survival (OS) was analyzed using Cox regression analysis. Results. Among 3,127 patients, the mean number of RLN was 22, and positive lymph node (LN) was found in 668 (21.4%) patients. X-tile plots identified “21” and “16” as the optimal cutoff value of RLN to divide the patients into two groups in terms of PFS and OS separately. In all patients, the number of RLN was not associated with PFS ( P = 0.182 ) or OS ( P = 0.193 ). Moreover, in both LN positive and negative patients, the number of RLN was not associated with either PFS ( P = 0.212 and P = 0.540 , respectively) or OS ( P = 0.173 and P = 0.497 , respectively). Cox regression analysis showed that the number of RLN was not an independent prognostic factor for PFS or OS. Conclusion. If standardized RHPL was performed, the number of RLN was not an independent prognostic factor for survival of patients with FIGO stage IB-IIA CSCC.

scholarly journals Primary Malignant Melanoma of Brainstem Medulla Mimicking as Cavernoma – Case Report

2019 ◽  
pp. 1-5
Author(s):  
Adnan Naeem ◽  
Fatima Mubarak
Keyword(s):  
Case Report ◽  
Malignant Melanoma ◽  
Brain Stem ◽  
Medulla Oblongata ◽  
Rare Case ◽  
Malignant Neoplasm ◽  
Surgical Excision ◽  
Primary Malignant Melanoma ◽  
Hyperintense Lesion ◽  
Neoplastic Lesion

Aim of this case report is to present a rare case of primary malignant melanoma of brain stem at the region of medulla oblongata mimicking as cavernoma. 40-year-old male presented with vertigo, headache, dizziness for 1 month. MRI showed pear shaped T1 hyperintense lesion at medulla oblongata and predominantly hypointense on T2 with focal area of hemorrhage. Lesion showed diffuse enhancement on postcontrast images. On plain CT lesion was Hyperdense. It was initially reported as Cavernoma. Surgical excision of lesion was done with per-op findings of solid, dark maroon colored lesion with hemorrhage. Histopathology showed neoplastic lesion with abundant melanin pigment deposition. The lesion was finally diagnosed as Malignant neoplasm with features favoring Malignant Melanoma.

Sign in / Sign up

Export Citation Format

Share Document